Shares are down in the year to date and 20% off their 52-week high, but analysts see 30% upside ahead for Pfizer.

TOKYO -- Roughly 2.5 million doses of oral COVID-19 medication bought by the Japanese government during the pandemic expired ...

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the Donald Trump administration's policies. Health care stocks can often be a solid defensive play in an ...

A meta-analysis of 187 trials shows that Paxlovid and remdesivir reduce the risk for hospitalization in patients with mild-to ...

Research shows that COVID tends to spike twice annually — once in the winter and once in the summer, and, like past years, ...

If you get COVID-19, one drug, Paxlovid, is the drug of choice. But for some who take it, COVID symptoms return again a few weeks later. Researchers are studying what ...

PFE trades above its 50-day average for over a month, signaling bullish momentum despite COVID revenue declines and patent ...

A Wall Street maxim states, “Twenty percent of investors who want to make money are in stocks, while the other 80 percent who ...

Scientists are currently studying how well people are protected against severe disease from XFG. Researchers conducted lab ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

Encounter-level factors played a key role in limiting outpatient COVID-19 treatment for Black and Latino patients.